VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

158.83

-0.72 (-0.45%)

As of 11:00AM EDT. Market open.

Stock chart is not supported by your current browser

Previous Close	159.55
Open	159.61
Bid	158.88 x 100
Ask	159.02 x 100
Day's Range	158.29 - 160.78
52 Week Range	113.66 - 178.15
Volume	334,424
Avg. Volume	1,770,943

Market Cap	40.482B
Beta	1.94
PE Ratio (TTM)	152.87
EPS (TTM)	1.04
Earnings Date	Apr 26, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	192.21

Trade prices are not sourced from all markets

All

News

Press Releases

Yahoo Finance Videolast month
NYSE trader: Facebook is too big to fail, so I'm sticking with tech stocks
Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Seana Smith live from the floor of the New York Stock Exchange to discuss the latest market moves.
Market Realistyesterday
Analysts’ Recommendations for Exelixis in April 2018
In February 2018, Exelixis (EXEL) and its partner Daiichi Sankyo announced that it had submitted a regulatory application for esaxerenone therapy to the Japanese Pharmaceutical and Medical Devices Agency for the treatment of individuals with hypertension. According to the prior agreement between Exelixis and Daiichi Sankyo, Exelixis is set to receive a milestone payment of $20 million from Daiichi Sankyo. Daiichi Sankyo’s regulatory application has been supported by the results of Phase 3 trials evaluating the safety and efficacy of esaxerenone in individuals with essential hypertension compared to eplerenone.
Motley Fool2 days ago
3 Growth Stocks That Could Put Facebook's Returns to Shame
Shares of Facebook have rewarded its investors incredibly well, but these Fools think you should take a look at these three stocks instead.
Business Wire3 days ago
Vertex to Announce First Quarter 2018 Financial Results on April 26
Vertex Pharmaceuticals Incorporated will report its first quarter 2018 financial results on Thursday, April 26, 2018 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m.
Zacks4 days ago
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Motley Fool7 days ago
3 Top Healthcare Stocks to Buy in April
April could be the perfect time to pick up shares in these top healthcare stocks.
Market Realist9 days ago
Jakafi Continues to Be Strong Growth Driver for Incyte in 2018
Incyte has projected Jakafi’s GAAP (generally accepted accounting principles) and non-GAAP revenues for full-year 2018 to fall in the range of $1.35 billion to $1.4 billion. This revenue performance could be driven by an anticipated rise in demand for the drug in existing rare blood cancer indications of myelofibrosis (or MF) and polycythemia vera (or PV) as well as from potential new indications such as graft versus host disease (or GVHD) and essential-thrombocythemia (or ET). Jakafi has been granted orphan drug designation in MF, PV, ET, GVHD, and acute lymphoblastic leukemia (ALL) indications.
Market Realist9 days ago
What Analysts Recommend for Incyte in April 2018
On April 6, 2018, Incyte (INCY) reported unfavorable results from its phase 3 ECHO-301/KEYNOTE-252 study, which evaluated the potential of the company’s investigational therapy, epacadostat, combined with Merck’s (MRK) Keytruda, in patients suffering from unresectable or metastatic melanoma as compared to those treated with Keytruda monotherapy. The trial failed to meet its first primary endpoint of improvement in progression-free survival and is also not expected to meet the second primary endpoint of overall survival. This news has had a drastic impact on Incyte’s stock, which fell ~22.9% from $83.07 on April 5, 2018, to $64.02 on April 6, 2018, and reduced the company’s market capitalization by approximately $3.5 billion.
Barrons.com9 days ago
Vertex Is Worth More Than You Think
Shares of Vertex Pharmaceuticals (VRTX) have easily outrun the market year-to-date, rising 8%, and the drug maker has notched returns of more than 42% in the past year. Analyst Hartaj Singh reiterated an Outperform rating and $190 price target on the shares Wednesday, but notes that Vertex could see as much as 50% upside to that target, which would put the shares at $285.
InvestorPlace14 days ago
10 Healthcare Stocks to Stave Off the Market Flu
While the markets run up and down because tech stocks are doing one thing or another, or retailers struggle to improve same-store sales, there isn’t much debate about the future of the healthcare sector.Source: Shutterstock
Market Realist17 days ago
Analysts’ Recommendations for BioMarin Pharmaceutical
A Post-4Q17 Update on BioMarin Pharmaceuticals
Market Realist17 days ago
BioMarin Pharmaceutical’s Drugs in 4Q17 and Fiscal 2017
A Post-4Q17 Update on BioMarin Pharmaceuticals
Market Realist22 days ago
Why Regeneron Pharmaceuticals’ Stock Price Fell
Who Is Watching Regeneron Pharmaceuticals?Reasons for the drop in Regeneron’s stock price
Business Wire22 days ago
Vertex Appoints Kimberly A. White as Senior Vice President and Chief Communications Officer
Vertex Pharmaceuticals Incorporated today announced that Kimberly A. White has been appointed Senior Vice President and Chief Communications Officer. Ms. White will begin her role with Vertex on May 21, 2018, and will report to Michael J.
Simply Wall St.24 days ago
Is Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) PE Ratio A Signal To Sell For Investors?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is currently trading at a trailing P/E of 157.1x, which is higher than the industry average of 27.5x. While VRTX might seem like a stock toRead More...
Motley Fool24 days ago
Investing in These Stocks Now Could Make You a Millionaire Retiree
These stocks have the right ingredients for achieving retirement goals.
Market Realist29 days ago
A Look at Incyte’s Valuation in March 2018
Who’s Watching Incyte Corporation in March 2018?Incyte Corporation
Markitlast month
See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX
Investopedialast month
12 Growth Stocks That Will Win Long Term: Goldman
Goldman Sachs expects growth stocks to enjoy continued outperformance, including these.
Motley Foollast month
3 Highest-Growth Stocks in the Market Today
All these companies promise turbocharged profit growth in the years ahead, but only two deserve a spot on your watch list.
TheStreet.comlast month
Trying the Long Side of Vertex's Stock Again
After pharmaceutical company breaks out, charts suggest now is the time to go back in.
Investor's Business Dailylast month
Why A Biopharma Buying Spree May Target AstraZeneca, Bristol
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Investor's Business Dailylast month
117 Top-Rated Mutual Funds Own Shares In This Potential Breakout Stock
PRA Health Sciences, just voted the Best CRO in Asia, may soon put its new buy point on trial.
Motley Foollast month
Why CRISPR Therapeutics Slipped 10% on Thursday
News from another company could be sparking a sell-off.
Motley Foollast month
7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock
The only "problem" mentioned by Vertex CEO Jeff Leiden? It's accumulating cash rapidly.